文献速递银屑病与炎症性皮肤病

GP2015与依那西普原研药多次互换不影响慢性斑块状银屑病疗效、安全性和免疫原性:EGALITY III期30周结果

Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-11-02

EGALITY是一项III期确证性研究,纳入531例斑块状银屑病患者,比较GP2015(依那西普生物类似药)与原研药ETN的疗效、安全性和免疫原性,并评估反复互换的影响。TP2期间,互换组与持续治疗组在PASI 50/75/90应答率、PASI评分变化及不良事件发生率上相似,两组均未出现结合抗药抗体阳性。

要点

  • GP2015与原研依那西普多次互换后30周内疗效与安全性无差异。
  • 互换组与持续治疗组PASI 50/75/90应答率在所有时间点均相似。
  • 两组均未检出结合抗药抗体阳性。

核心结论

  • TP2期间,GP2015与ETN反复互换组与持续治疗组在疗效、安全性和免疫原性方面相似。
  • 短期数据显示GP2015与ETN多次互换对临床数据无影响。

研究设计与样本

  • III期确证性研究,纳入531例斑块状银屑病患者。
  • TP1随机1:1接受GP2015或ETN每周两次皮下注射;第12周PASI 50应答者再随机进入TP2,持续原治疗每周一次或进行三次连续互换直至第30周。
  • TP2分析比较两个持续治疗组(pooled continued)与两个互换组(pooled switched)。

主要发现

  • TP2期间,互换组与持续治疗组在所有时间点的PASI 50、PASI 75和PASI 90应答率及PASI评分较基线变化百分比均相似。
  • 治疗中出现的不良事件发生率:互换组36.7%,持续治疗组34.9%,包括注射部位反应。
  • TP2期间两组均无患者结合抗药抗体阳性。

关键数值与推荐

  • 第12周PASI 50应答者进入TP2再随机。
  • TP2期间持续治疗组每周一次给药。
  • 互换组进行三次连续治疗互换直至第30周。

临床怎么用

  • 短期数据支持GP2015与原研依那西普之间多次互换不影响疗效、安全性和免疫原性。

局限性

  • 本文仅报告TP2至第30周的结果,长期互换影响需进一步观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: EGALITY was a phase III confirmatory efficacy and safety study conducted in patients with plaque-type psoriasis as a part of totality of evidence gathered during the development of GP2015, an etanercept biosimilar. OBJECTIVE: To demonstrate equivalent efficacy and comparable safety and immunogenicity of GP2015 and the etanercept originator product (ETN, Enbrel® ) and evaluate effects of repeated switching between GP2015 and ETN. Results for efficacy, safety and immunogenicity during treatment period (TP) 2 (TP2) are presented pooling the two continued treatment arms (pooled continued) versus the two treatment arms with repeated switches (pooled switched). METHODS: Patients (n = 531) were randomized 1:1 to self-administer GP2015 or ETN twice-weekly subcutaneously during TP1. Patients with a ≥50% improvement in Psoriasis Area and Severity Index (PASI 50) at week 12 were re-randomized for TP2 to continue the same treatment at once-weekly dosing or to undergo three consecutive treatment switches between GP2015 and ETN until week 30. Patients continued the last-assigned treatment during TP2, until week 52. RESULTS: Mean (standard deviation [SD]) PASI scores at baseline were similar in patients who underwent multiple switches compared to those with continued treatments during TP2. During TP2, PASI 50, PASI 75 and PASI 90 response rates, percent change from baseline in PASI scores and all other efficacy parameters were similar between the pooled switched and pooled continued treatment groups at all time points. The incidence of treatment-emergent adverse events including injection site reactions was comparable between the pooled switched (36.7%) and pooled continued (34.9%) groups. None of the patients in either treatment group were positive for binding anti-drug antibodies in TP2. CONCLUSION: Treatment efficacy, safety and immunogenicity were similar between the pooled continued and pooled switched treatments during TP2, indicating that there are no effects in the short term on clinical data of multiple switches between GP2015 and ETN.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Gerdes S, Thaçi D, Griffiths CEM, et al. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study. J Eur Acad Dermatol Venereol. 2017. PMID: 28960486. doi:10.1111/jdv.14605

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。